CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

A small business needs to protect its intellectual property, which includes its business name and logo. These items distinguish the business from the competition by generating brand recognition ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

More Bonds of Novo Nordisk Finance [Netherlands] B.V. About the Novo Nordisk Finance [Netherlands] B.V.-Bond (XS3002553538) The Novo Nordisk Finance [Netherlands] B.V.-Bond has a maturity date of ...

Novo Nordisk Pharma (Thailand) Ltd. is advancing its commitment to sustainable weight management among Thais through the launch of the “From My Weight to My Heart” campaign, aimed at reducing ...

In its first-quarter 2025 investor letter, ClearBridge Large Cap Value Strategy highlighted stocks such as Novo Nordisk A/S (NYSE ... Disruption is the New Name of the Game: Let’s face it ...

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs ... For hundreds of dollars less than the name ...